Capital Group Private Client Services Inc. Trims Stock Position in Axon Enterprise, Inc $AXON

Capital Group Private Client Services Inc. lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 85.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,313 shares of the biotechnology company’s stock after selling 30,026 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Axon Enterprise were worth $3,813,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. raised its position in Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital boosted its position in Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 14 shares in the last quarter. Evergreen Capital Management LLC grew its stake in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. STF Management LP increased its holdings in shares of Axon Enterprise by 1.4% during the 2nd quarter. STF Management LP now owns 1,164 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 16 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Axon Enterprise by 2.5% during the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 16 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Analysts and market pieces note AXON’s strong recent momentum and demand — the stock has climbed ~28–29% over the past month on robust device and software uptake, which supports the company’s multi-year growth narrative. Axon Stock Rises 28.6% in a Month
• Positive Sentiment: Zacks highlights earnings growth and price strength as reasons AXON remains a stock to watch, reinforcing the view that recent results (revenue and EPS beats) underpin upside expectations. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: Coverage referencing AppLovin’s “AXON” product (AppLovin’s AXON 2.0 ad engine and related studies) is generating industry attention but refers to a different company/product; this can create headline noise and investor confusion rather than direct fundamental impact on Axon Enterprise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Neutral Sentiment: Related AppLovin/marketing partnership and Kantar report items (which reference “Axon by AppLovin”) and Bank of America commentary on AppLovin add sector-level noise but are not company-specific catalysts for AXON. Mobile Gaming Now a Mainstream Consumer Channel Driving Purchase Impact for Brands Bank of America Reaffirms Buy on AppLovin
• Neutral Sentiment: Short-interest notices in recent feeds show anomalous/zero values and NaN changes — the published short data looks unreliable and is unlikely to be a meaningful immediate driver. (No reliable short-covering signal shown.)
• Negative Sentiment: Market reaction today looks driven by profit-taking after the post-earnings run-up and valuation sensitivity; QuiverQuant notes AXON slid as investors digested a rich valuation and a lack of fresh company-specific catalysts. Insider selling activity (multiple recent sales reported) also adds to near-term caution. Axon slips as investors digest rich valuation
• Negative Sentiment: Relative-performance coverage flags that AXON is underperforming some peers today — a reminder investors are rotating within the sector and favoring names with more attractive near-term risk/reward. Axon Enterprise Inc. stock underperforms Tuesday

Insider Activity at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the sale, the chief executive officer directly owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 26,634 shares of company stock valued at $14,963,095. 5.70% of the stock is owned by corporate insiders.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $529.97 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The firm has a fifty day moving average of $534.81 and a 200 day moving average of $613.75. The firm has a market cap of $42.61 billion, a PE ratio of 348.67, a PEG ratio of 11.93 and a beta of 1.46. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.08 earnings per share. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Craig Hallum reaffirmed a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 25th. Needham & Company LLC decreased their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Piper Sandler lowered their target price on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Citigroup restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.